Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Mais filtros











Base de dados
Intervalo de ano de publicação
1.
J Biomater Sci Polym Ed ; 15(9): 1111-9, 2004.
Artigo em Inglês | MEDLINE | ID: mdl-15503629

RESUMO

Two different types of hyaluronic acid (HA) hydrogels were synthesized by crosslinking HA with divinyl sulfone (DVS) and poly(ethylene glycol)-divinyl sulfone (VS-PEG-VS). Vitamin E succinate (VES), an anti-inflammatory drug, and bovine serum albumin (BSA), a model of anti-inflammatory protein drugs, were loaded into the gels and their release kinetics were measured in vitro. VES and BSA released with a burst from both HA hydrogels during the first few hours, and release continued gradually for several days. The rate of release from HA-VS-PEG-VS-HA hydrogels was faster than that from HA-DVS-HA hydrogels, presumably due to the lower crosslink density in the former. The anti-inflammatory action of released VES was tested by incubating peripheral blood mononuclear cells (PBMC) on HA hydrogels with and without VES in the gel. The number of cells adhering on HA hydrogels was very low compared to that on tissue culture polystyrene (TCPS), which might be one of the important advantages of using HA hydrogels for implant coatings or tissue engineering applications. ELISA test results showed that the tumor necrosis factor-alpha (TNF-alpha) concentration was very low in the supernatant of the wells containing the HA hydrogel with VES in contact with the activated macrophages compared to that without VES. This is probably the effect of the released VES reducing the production of anti-inflammatory cytokine, TNF-alpha. HA hydrogels containing anti-inflammatory drugs may have potential for use in tissue engineering and also as biocompatible coatings of implants.


Assuntos
Anti-Inflamatórios não Esteroides/administração & dosagem , Materiais Biocompatíveis/síntese química , Hidrogéis/síntese química , Vitamina E/análogos & derivados , Animais , Materiais Biocompatíveis/química , Bovinos , Reagentes de Ligações Cruzadas , Sistemas de Liberação de Medicamentos , Humanos , Ácido Hialurônico/química , Hidrogéis/química , Técnicas In Vitro , Ativação de Macrófagos , Teste de Materiais , Microscopia Eletrônica de Varredura , Estrutura Molecular , Polietilenoglicóis/síntese química , Polietilenoglicóis/química , Soroalbumina Bovina/administração & dosagem , Sulfonas/química , Tocoferóis , Vitamina E/administração & dosagem
2.
J Biomed Mater Res A ; 70(2): 328-34, 2004 Aug 01.
Artigo em Inglês | MEDLINE | ID: mdl-15227678

RESUMO

Pathologic calcification is the leading cause of the clinical failure of glutaraldehyde-fixed bovine pericardium used in bioprosthetic valves. A novel surface modification of glutaraldehyde fixed bovine pericardium was carried out with high molecular weight hyaluronic acid (HA). HA was chemically modified with adipic dihydrazide (ADH) to introduce hydrazide functional groups onto the HA backbone. Glutaraldehyde-fixed bovine pericardium (GFBP) was modified by grafting this HA to the free aldehyde groups on the tissue via the hydrazide groups. Following a 2-week subcutaneous implantation in osteopontin (OPN)-null mice, the calcification of HA-modified bovine pericardium was drastically reduced (by 84.5%) compared to positive controls (tissue without HA-modification) (p = 0.005). The calcification-mitigating effect of HA surface modification was also confirmed by microscopic analysis of explanted tissue stained with Alizarin Red S for calcium.


Assuntos
Bioprótese , Calcinose/prevenção & controle , Próteses Valvulares Cardíacas , Pericárdio/transplante , Animais , Materiais Biocompatíveis/química , Bioprótese/efeitos adversos , Bovinos , Feminino , Fixadores , Glutaral , Próteses Valvulares Cardíacas/efeitos adversos , Humanos , Ácido Hialurônico/química , Teste de Materiais , Camundongos , Camundongos Knockout , Osteopontina , Sialoglicoproteínas/deficiência , Sialoglicoproteínas/genética
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA